FSD-C10

FSD-C10 is a **novel, selective Rho kinase (ROCK) inhibitor** and a derivative of fasudil, designed to offer neuroprotective and anti-inflammatory effects with improved safety and administration profiles compared to fasudil. FSD-C10 preferentially inhibits ROCK II over ROCK I, which may contribute to reduced vasodilation and cytotoxicity. In preclinical studies, FSD-C10 was shown to ameliorate disease severity in animal models of multiple sclerosis (experimental autoimmune encephalomyelitis, EAE), improve learning and memory impairment in Alzheimer's disease models, suppress oxidative stress-induced apoptosis in brain microvascular endothelial cells, attenuate CNS inflammation, and promote neuroprotection and neurotrophic factor expression. Administration by intranasal route has demonstrated efficient CNS delivery and immumodulation, altering cytokine production towards an immunoregulatory profile and reducing neuroinflammation and demyelination. The drug exhibits potential for long-term use due to its low cytotoxicity and favorable safety profile[1][2][3][4][5][6][7][10].

Other names

FSD-C10FSD-C-10FSD-C 10